Princess Margaret Cancer Centre in Toronto officially opened enrolment Friday for a Phase I/II clinical trial of an investigational oral drug that its lead pancreatic cancer specialist says doubled survival time in laboratory and early human data, marking a potentially significant step forward for one of oncology's most lethal diagnoses.

Dr. Steven Gallinger, head of the pancreatic cancer programme at Princess Margaret and University Health Network, confirmed that the trial will initially recruit up to 40 patients with locally advanced or metastatic pancreatic ductal adenocarcinoma who have progressed on or are ineligible for standard gemcitabine-based regimens. The compound targets a metabolic vulnerability unique to pancreatic tumour cells, allowing the pill to be administered at home rather than via intravenous infusion — a quality-of-life advantage the research team considers clinically meaningful.

The announcement follows coverage earlier this week in which Gallinger stated publicly that he expected the trial to open imminently, describing preliminary data in which median overall survival roughly doubled compared with historical controls on standard-of-care chemotherapy. Pancreatic cancer carries a five-year survival rate below 12 percent globally, making even modest improvements in median survival scientifically and emotionally significant for patients and families.

Canadian Cancer Society chief scientific officer Dr. Shana Adamson, who was briefed on the trial design, noted that the oral delivery mechanism addresses a longstanding barrier to care for patients living far from major cancer centres. "If the efficacy signal holds in a randomised setting, this could redefine outpatient management of advanced pancreatic cancer across Canada and beyond," she said in a statement released Friday morning.

Trial sites at Vancouver General Hospital and the Jewish General Hospital in Montreal are expected to join the consortium by late summer 2026, expanding total enrolment capacity to approximately 120 participants across three provinces. Interim safety and pharmacokinetic data are anticipated for presentation at the 2027 American Society of Clinical Oncology annual meeting, with full efficacy results projected by late 2028 pending enrolment pace.